We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Apple Inc., Tesla, Inc., and Johnson & Johnson
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 1, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. (AAPL - Free Report) , Tesla, Inc. (TSLA - Free Report) , and Johnson & Johnson (JNJ - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Apple, Tesla and Johnson & Johnson
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA), and Johnson & Johnson (JNJ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Apple have outperformed the S&P 500 over the past year (+27.8% vs. +19.3%), with the block-busted December-quarter results expected to help sustain the stock's momentum despite the ongoing market volatility. The Zacks analyst believes that Apple has been benefiting from momentum in the Services business, strong adoption of Apple Pay and growing Apple Music subscriber base.
Apple’s first-quarter fiscal 2022 results benefited from strong iPhone sales and continued momentum in the Services business amid significant supply-chain constraints. Mac also witnessed a strong quarter on the back of high demand for the newly redesigned MacBook Pro powered by M1 chip. Apple, however, did not provide revenue guidance for the second quarter due to pandemic-related uncertainties.
Tesla shares have gained +19.3% over the past six months against the Zacks Domestic Automotive industry’s gain of +5.9%. The Zacks analyst believes that robust demand for Models 3 and Y has been buoying Tesla's revenues.
Tesla hit record deliveries and an all-time high gross margin in Q4. Despite the global chip crunch, Tesla’s vehicle deliveries jumped 90% in 2021. TSLA is also poised to benefit from its Shanghai gigafactory. High R&D and SG&A costs along with massive capex plans are likely to hurt Tesla’s margins and cash flows in the quarters ahead.
Shares of Johnson & Johnson have gained +6.1% in the last three months against the Zacks Large Cap Pharmaceuticals industry’s gain of +4.1%. The Zacks analyst believes that J&J has been making rapid progress with its pipeline and line extensions, with several pivotal data readouts and regulatory milestones expected in the near term.
The Pharma unit has also been performing at above-market levels on the back of Darzalex and Stelara and contribution from newer drugs, Erleada and Tremfya as well as the COVID-19 vaccine. Sales in Consumer unit are improving, withstanding external supply constraints. Headwinds like generic competition and pricing pressure, however, continue to stress margins.
Other noteworthy reports we are featuring today include Intel Corp. (INTC) and PetroChina Company Ltd. (PTR).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Apple Inc., Tesla, Inc., and Johnson & Johnson
For Immediate Release
Chicago, IL – February 1, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. (AAPL - Free Report) , Tesla, Inc. (TSLA - Free Report) , and Johnson & Johnson (JNJ - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Apple, Tesla and Johnson & Johnson
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA), and Johnson & Johnson (JNJ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Apple have outperformed the S&P 500 over the past year (+27.8% vs. +19.3%), with the block-busted December-quarter results expected to help sustain the stock's momentum despite the ongoing market volatility. The Zacks analyst believes that Apple has been benefiting from momentum in the Services business, strong adoption of Apple Pay and growing Apple Music subscriber base.
Apple’s first-quarter fiscal 2022 results benefited from strong iPhone sales and continued momentum in the Services business amid significant supply-chain constraints. Mac also witnessed a strong quarter on the back of high demand for the newly redesigned MacBook Pro powered by M1 chip. Apple, however, did not provide revenue guidance for the second quarter due to pandemic-related uncertainties.
(You can read the full research report on Apple here >>>)
Tesla shares have gained +19.3% over the past six months against the Zacks Domestic Automotive industry’s gain of +5.9%. The Zacks analyst believes that robust demand for Models 3 and Y has been buoying Tesla's revenues.
Tesla hit record deliveries and an all-time high gross margin in Q4. Despite the global chip crunch, Tesla’s vehicle deliveries jumped 90% in 2021. TSLA is also poised to benefit from its Shanghai gigafactory. High R&D and SG&A costs along with massive capex plans are likely to hurt Tesla’s margins and cash flows in the quarters ahead.
(You can read the full research report on Tesla here >>>)
Shares of Johnson & Johnson have gained +6.1% in the last three months against the Zacks Large Cap Pharmaceuticals industry’s gain of +4.1%. The Zacks analyst believes that J&J has been making rapid progress with its pipeline and line extensions, with several pivotal data readouts and regulatory milestones expected in the near term.
The Pharma unit has also been performing at above-market levels on the back of Darzalex and Stelara and contribution from newer drugs, Erleada and Tremfya as well as the COVID-19 vaccine. Sales in Consumer unit are improving, withstanding external supply constraints. Headwinds like generic competition and pricing pressure, however, continue to stress margins.
(You can read the full research report on Johnson & Johnson here >>>)
Other noteworthy reports we are featuring today include Intel Corp. (INTC) and PetroChina Company Ltd. (PTR).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.